Skip to main content
. 2021 Oct 28;12:753477. doi: 10.3389/fimmu.2021.753477

Figure 4.

Figure 4

(A) Relative abundance of α-ketoglutarate in PBS- and Slit2-treated WT and PyMT mouse BMDMs. (B) Relative abundance of succinic acid in PBS- and Slit2-treated WT and PyMT mouse BMDMs. (C) Ratio of α-ketoglutarate:succinic acid in PBS- and Slit2-treated WT and PyMT mouse BMDMs. (D) Relative abundance of α-ketoglutarate in PBS- and Slit2-treated human BMDMs. (E) Relative abundance of succinic acid in PBS- and Slit2-treated human BMDMs. (F) Ratio of α-ketoglutarate: succinic acid in PBS- and Slit2-treated human BMDMs. Images represent n = 4–6/group. *p < 0.05, assessed by unpaired t-test.